News

JUNE 22, 2020 - BOSTON, MA

Amicrobe awarded additional $4.6M from CARB-X to accelerate development of Amicidin-β Solution and prototype a new product, Amicidin-β/EF

MAY 28, 2020 - CARB-X WEBINAR

Dr. Bevilacqua presents at CARB-X webinar on "Preparing for an FDA Pre-IND Meeting: Planning for Success"

FEBRUARY 12, 2020 - CARLSBAD, CA

Amicrobe raises $2.5 million through convertible debt offering

NOVEMBER 7, 2019 - WASHINGTON, DC

Dr. Bevilacqua an invited speaker at the World Antimicrobial Resistance Congress

NOVEMBER 5, 2019 - SILVER SPRING, MD

Amicrobe holds pre-IND face-to-face meeting with the FDA on Amicidin-β Solution

SEPTEMBER 5, 2019 - BOSTON, MA

Dr. Bevilacqua an invited panelist at ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

AUGUST 27, 2019 - SAN DIEGO, CA

Dr. Bevilacqua gives invited presentation "Amicidin-alpha and Amicidin-beta: Amino acid block copolymers in development for prevention and treatment of infection in surgery and trauma" at the Fall 2019 American Chemical Society conference

AUGUST 20, 2019 - KISSIMMEE, FL

Amicrobe presents at the 2019 Military Health System Research Symposium

OCTOBER 18, 2018 - SILVER SPRING, MD

Amicrobe holds pre-IND face-to-face meeting with the FDA on Amicidin-α Surgical Gel

AUGUST 21, 2018 - KISSIMMEE, FL

Amicrobe presents at the 2018 Military Health System Research Symposium

AUGUST 20, 2018 - SILVER SPRING, MD

Dr. Bevilacqua an invited panelist for FDA workshop “Development of Non-Traditional Therapies for Bacterial Infections”

READ MORE

JUNE 14, 2018 - WASHINGTON, DC

Dr. Michael Bevilacqua, Amicrobe’s founder and CEO, was an invited speaker and panelist at an FDA supported meeting on the topic of developing “… Emerging Non-traditional Antibiotics”.

APRIL 24, 2018 - CARLSBAD, CA

Amicrobe, Inc., developer of novel technology for antibiotic resistance, adds safety application to intellectual property portfolio

APRIL 17, 2018 - CARLSBAD, CA

Antimicrobial innovator Amicrobe, Inc. positions managment team in anticipation of product trials

OCTOBER 24, 2017 - CARLSBAD, CA

Amicrobe, Inc. announces receipt of $2.48M award from award from CARB-X to accelerate development of Amicidin-β for treatment of life-threatening infections in surgery and trauma

SEPTEMBER 6, 2017 - CARLSBAD, CA

Amicrobe completes Series C capital raise of $5M

3142 Tiger Run Court - Suite 101, Carlsbad, California 92010

+1 (888) 490-1180